whitepaper
Webinar series: Considerations for successful CRISPR-based cell line engineering
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
List view / Grid view
Personalised Medicine
video
On-demand webinar: Leveraging advances in predesigned synthetic sgRNA for highly functional and specific CRISPR-Cas9 gene knockout
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
whitepaper
Article: Tips for successful editing in T cells
Horizon article on the recipe for success for CRISPR editing in T cells.
whitepaper
Article: Common CRISPR pitfalls and how to avoid them
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
news
Organoids grown from stem cells could treat children with intestinal failure
Intestinal organoids have been grown by researchers using stem cells from patient tissues that could lead to personalised transplants for children with intestinal failure.
whitepaper
Application note: Human iPS cells modified with Edit-R™ CRISPR-Cas9 reagents
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
webinar
Untangling gene expression complexity with pooled CRISPR screens coupled to single-cell transcriptome analysis
4 September 2020 | By Horizon Discovery
During this on-demand webinar we present data showing how Horizon’s CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
whitepaper
Application note: The effect of column hardware on the analysis of synthetic oligonucleotides by LC-MS
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
whitepaper
Application note: Effect of temperature on single stranded oligonucleotide analysis
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterisation of oligos, specifically by ion-pair reversed phase liquid chromatography (IPRPLC), can be quite challenging.
whitepaper
Application note: Effect of perfluorinated alcohols in impurity analysis for synthetic oligonucleotides
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
whitepaper
Application note: Effect of alkylamine based Ion-pairing reagents in analysis of siRNA
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
whitepaper
Application note: Comparison of fully porous and superficially porous particles for the analysis of synthetic oligonucleotides
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.
webinar
Mobile phase optimisation for oligonucleotide analytical methods by LC-MS
1 July 2020 | By Phenomenex
In this on-demand webinar, we provide an overview of nucleic acid therapeutics and discuss the chromatographic challenges associated with oligonucleotides. We also explore modulation of the mobile phase additives alkylamine ion pair and perfluorinated alcohols. Finally, we will show how optimisation of mobile phase can improve not only chromatographic performance…
webinar
Drug repurposing approaches to fast track development of new therapies for COVID-19
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
webinar
Improving cell-based assays and their future in drug discovery
15 June 2020 | By Horizon Discovery
Watch our on-demand webinar with Horizon Discovery which summarises the challenges in translating promising pre-clinical therapeutic candidates into clinical success.